Asthma Clinical Trials

Clinical research is currently underway in our division to examine the mechanisms of asthma and potential treatments and therapies to combat this disease. Our researchers conduct research in conjunction with the Duke Asthma, Allergy, and Airway Center.

Current Clinical Trials

The following clinical research initiatives are being conducted in our division:

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge: The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study) for drug targets.

Principal Investigator: John Sundy, MD, PhD

 

Genetics of Asthma — Bronchoscopy Studies: The purpose of this study is to identify the mediators and genes in airway epithelial and BAL cells that are differentially regulated following inhalation of endotoxin lipopolysaccharide (LPS) among study participants with allergic asthma and normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis and asthma susceptibility. 

Principal Investigator: John Sundy, MD, PhD

 

Lansoprazole to Treat Children With Asthma (SARCA): This study will evaluate the effectiveness of lansoprazole, a medication commonly used to treat GERD, in improving asthma control and reducing symptoms in children with poorly controlled asthma.

Principal Investigator: John Sundy, MD, PhD

 

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1: The purpose of the study is to determine the role of nitric oxide (NO) in asthma. We determine the effect of promoter polymorphisms in the gene for the NO producing enzyme, nitric oxide synthase (NOS2), on exhaled NO in healthy African Americans and Caucasians. We compare exhaled NO levels between African Americans and Caucasians. Information on race or ethnicity, serum samples, blood pressure, exhaled breath condensate, and health questionnaires will be collected.

Sub-investigator: John Sundy, MD, PhD

 

Pathogenesis and Genetics of Environmental Asthma Ozone Study: The goals of the research are designed to accomplish genetic association studies of candidate genes in healthy normal individuals exposed to 0.2 ppm for 2.25 hours with intermittent exercise in order to search for associations between defined genotypes/haplotypes and three specific in vivo respiratory endpoints: a) change in FEV1 immediately after ozone exposure; b) change nonspecific bronchial reactivity as reflected in the change in methacholine PC20 FEV1 24 hours after ozone exposure; and c) change in lung epithelial integrity as reflected in the Clearance Halftime of technetium 24 hours after ozone exposure.

Principal Investigator: W Michael Foster, PhD

 

Role of TLR4 in Environmental Asthma: The overall goal of this project is to identify genes that are involved in the development of airflow obstruction and airway inflammation in asthmatics, and to determine whether polymorphisms in these differentially expressed genes predispose individuals to develop asthma.

Principal Investigator: John Sundy, MD, PhD

Enroll in an Asthma or Allergy Clinical Trial

Asthma and allergy trials: Our division has several investigators examining remodeling, host immune defense mechanisms, gene-environment interactions, and pharmacologic therapies. Visit DukeMedicine.org for a list of current clinical trials.